Generation and characterization of a target-selectively activated antibody against epidermal growth factor receptor with enhanced anti-tumor potency

Panitumumab, as a commercially available antibody, is an effective anticancer therapeutic against epidermal growth factor receptor (EGFR), although it exerts weak antibody-dependent cell-mediated cytotoxicity (ADCC) activity owing to its IgG2 nature. Here, we firstly engineered panitumumab by grafti...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:MAbs
Autors principals: Yang, Yun, Guo, Qingcheng, Xia, Mao, Li, Yantao, Peng, Xiaoyun, Liu, Tao, Tong, Xin, Xu, Jin, Guo, Huaizu, Qian, Weizhu, Hou, Sheng, Dai, Jianxin, Wang, Hao, Liu, Rong, Guo, Yajun
Format: Artigo
Idioma:Inglês
Publicat: Taylor & Francis 2015
Matèries:
Reports
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC4622528/
https://ncbi.nlm.nih.gov/pubmed/25679409
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/19420862.2015.1008352
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars